Telswit‑AM is a fixed-dose antihypertensive combination tablet comprising Amlodipine 5 mg (a calcium channel blocker) and Telmisartan 40 mg (an angiotensin II receptor blocker). This formulation harnesses synergistic mechanisms to reduce peripheral resistance and stabilize blood pressure levels with enhanced compliance via once-daily dosing.
Therapeutic Benefits:
-
Amlodipine relaxes vascular smooth muscle to reduce afterload
-
Telmisartan blocks angiotensin II receptors, lowering vasoconstriction and aldosterone-mediated water retention
-
Combined effects improve blood pressure control and reduce cardiovascular risk
Indications:
-
Essential hypertension – monotherapy or in patients uncontrolled on single agents
-
Clinical scenarios requiring dual blockade of calcium channels and renin-angiotensin system
Recommended Dose:
One tablet once daily, irrespective of meals. Individual response should be monitored, and dosage adjusted by the physician.
Warnings & Monitoring:
-
Monitor renal function and potassium levels periodically
-
Use with caution in patients with heart failure or volume depletion
-
Contraindicated during pregnancy, breastfeeding, and in bilateral renal artery stenosis
-
May cause peripheral edema, dizziness, or fatigue
Packaging & Storage:
Store in airtight blister packs at room temperature, protected from moisture and children’s reach.
